IMUNOVIR

This brand name is authorized in Canada, Ireland, UK.

Active ingredients

The drug IMUNOVIR contains one active pharmaceutical ingredient (API):

1	Inosine pranobex UNII W1SO0V223F - INOSINE PRANOBEX
	Inosine pranobex is a synthetic purine derivative with immunomodulatory and antiviral properties, which result from an apparent in vivo enhancement of host immune responses due to the drug.
	Read more about Inosine pranobex

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
IMUNOVIR Tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AX05	Inosine pranobex	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AX Other antivirals
Discover more medicines within J05AX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02240713
GB	Medicines & Healthcare Products Regulatory Agency	40018
IE	Health Products Regulatory Authority	27964